1. Home
  2. VVX vs PHVS Comparison

VVX vs PHVS Comparison

Compare VVX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo V2X Inc.

VVX

V2X Inc.

HOLD

Current Price

$65.72

Market Cap

2.0B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$25.62

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVX
PHVS
Founded
2014
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
VVX
PHVS
Price
$65.72
$25.62
Analyst Decision
Buy
Buy
Analyst Count
10
9
Target Price
$62.60
$39.44
AVG Volume (30 Days)
397.9K
254.3K
Earning Date
02-23-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
791.53
N/A
EPS
2.51
N/A
Revenue
$4,419,142,000.00
N/A
Revenue This Year
$4.53
N/A
Revenue Next Year
$5.14
N/A
P/E Ratio
$25.94
N/A
Revenue Growth
5.10
N/A
52 Week Low
$41.08
$11.51
52 Week High
$65.50
$29.80

Technical Indicators

Market Signals
Indicator
VVX
PHVS
Relative Strength Index (RSI) 74.68 50.74
Support Level $54.09 $23.62
Resistance Level $56.38 $27.11
Average True Range (ATR) 1.87 1.51
MACD 1.05 -0.05
Stochastic Oscillator 91.12 40.33

Price Performance

Historical Comparison
VVX
PHVS

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: